| scholarly article | Q13442814 |
| P2093 | author name string | Haitao Zhang | |
| Debasis Mondal | |||
| Asim B Abdel-Mageed | |||
| David Mulholland | |||
| Krzysztof Moroz | |||
| Donna R Edwards | |||
| P2860 | cites work | Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence | Q28236158 |
| ONCOMINE: a cancer microarray database and integrated data-mining platform | Q28255103 | ||
| Role of the TMPRSS2-ERG gene fusion in prostate cancer | Q28269156 | ||
| PRL-3 phosphatase is implicated in ovarian cancer growth | Q28275403 | ||
| The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
| Integrative genomic profiling of human prostate cancer | Q29619905 | ||
| Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer | Q33863328 | ||
| DD3: a new prostate-specific gene, highly overexpressed in prostate cancer | Q33884277 | ||
| Molecular characterization of human prostate carcinoma cell lines | Q34266176 | ||
| Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells | Q36384761 | ||
| Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival | Q36918028 | ||
| Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes | Q36918116 | ||
| Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma | Q37426883 | ||
| PRL‐3 phosphatase and cancer metastasis | Q37807363 | ||
| Predicting high-risk disease using tissue biomarkers | Q38088126 | ||
| Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy. | Q38107795 | ||
| The nucleolus: an emerging target for cancer therapy | Q38129532 | ||
| Prostate cancer biomarkers: an update. | Q38185176 | ||
| The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation | Q38261521 | ||
| Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. | Q38467346 | ||
| Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration | Q38786529 | ||
| LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia | Q39009741 | ||
| An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer | Q39394220 | ||
| Phosphatase PRL-3 Is a Direct Regulatory Target of TGFβ in Colon Cancer Metastasis | Q39630626 | ||
| Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2. | Q39769653 | ||
| PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly | Q39851944 | ||
| Digital image analysis outperforms manual biomarker assessment in breast cancer. | Q39967968 | ||
| Quantitative imaging assay for NF-kappaB nuclear translocation in primary human macrophages. | Q40045324 | ||
| Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. | Q40146469 | ||
| PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation | Q40189743 | ||
| Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells | Q40291759 | ||
| Different subnuclear localization of wild-type and mutant p53 in human prostate-cancer cells. | Q41260779 | ||
| Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome | Q43685496 | ||
| Tumor immunobiological differences in prostate cancer between African-American and European-American men. | Q44513168 | ||
| PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer | Q46157962 | ||
| Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer | Q47811299 | ||
| Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells. | Q51587005 | ||
| PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. | Q51798437 | ||
| Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. | Q53519887 | ||
| E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. | Q53999986 | ||
| The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system | Q57307229 | ||
| Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer | Q84419666 | ||
| PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism | Q88727073 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P577 | publication date | 2017-11-20 | |
| P1433 | published in | International Journal of Oncology | Q6051527 |
| P1476 | title | PRL‑3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients |
Search more.